1.5900
07-2月-25 15:45:00
15 分の遅延
株式
-0.0300
-1.85%
本日の幅
1.5500 - 1.6200
ISIN
N/A
ソース
NASDAQ
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 9 2024 07:30:00 提供 Nasdaq GlobeNewswire